Caliper Expects Q4 Turnaround for Imaging Business Aided by New Spectrum Patent | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
Caliper Life Sciences officials are confident that the company’s IVIS imaging business will return to “strong double-digit” growth levels in the fourth quarter and beyond, following a decline in imaging sales during the third quarter.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.